Separately, Zacks Investment Research lowered BeyondAirInc . from a “hold” rating to a “sell” rating in a research note on Saturday.
Shares of XAIR stock traded down $0.14 during trading hours on Monday, hitting $4.36. The company had a trading volume of 1,673 shares, compared to its average volume of 19,947. BeyondAirInc . has a 12 month low of $3.11 and a 12 month high of $6.25. The company has a market cap of $48.35 million, a price-to-earnings ratio of -5.19 and a beta of -0.27. The stock’s fifty day moving average is $4.68.
BeyondAirInc . Company Profile
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
See Also: What is a good dividend yield?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.